close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade
Kodu・Aktsiate loetelu・Nanobiotix
Search

Nanobiotix

Suletud

18.12 2.84

Osta

Hinna uuendus 3. veebr 2026, 16:29 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.14

Max

18.22

Põhinäitajad

By Trading Economics

Sissetulek

-5.4M

Müük

27M

Kasumimarginaal

-20.208

Töötajad

103

EBITDA

1.1M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+29.36% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. apr 2026

Turustatistika

By TradingEconomics

Turukapital

878M

Eelmine avamishind

15.28

Eelmine sulgemishind

18.12

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. veebr 2026, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

DJ

Loe

2. veebr 2026, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

DJ

Loe

2. veebr 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

DJ

Loe

2. veebr 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

DJ

Loe

2. veebr 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

DJ

Loe

2. veebr 2026, 23:23 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

DJ

Loe

2. veebr 2026, 22:57 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Loe

2. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

DJ

Loe

2. veebr 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

DJ

Loe

2. veebr 2026, 21:51 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Loe

2. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Loe

2. veebr 2026, 21:49 UTC

Tulu

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

DJ

Loe

2. veebr 2026, 21:39 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Loe

2. veebr 2026, 21:36 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

DJ

Loe

2. veebr 2026, 21:34 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Loe

2. veebr 2026, 21:28 UTC

Omandamised, ülevõtmised, äriostud

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

DJ

Loe

2. veebr 2026, 21:23 UTC

Tulu

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

DJ

Loe

2. veebr 2026, 21:19 UTC

Tulu

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

DJ

Loe

2. veebr 2026, 21:17 UTC

Tulu

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

DJ

Loe

2. veebr 2026, 21:17 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Loe

2. veebr 2026, 21:10 UTC

Tulu

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Loe

2. veebr 2026, 21:08 UTC

Tulu

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

DJ

Loe

2. veebr 2026, 21:07 UTC

Tulu

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

DJ

Loe

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Net $608.7M >PLTR

DJ

Loe

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Rev $1.41B >PLTR

DJ

Loe

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

DJ

Loe

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

DJ

Loe

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q Adj EPS 25c >PLTR

DJ

Loe

2. veebr 2026, 21:05 UTC

Tulu

Palantir Technologies 4Q EPS 24c >PLTR

DJ

Loe

2. veebr 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

DJ

Loe

Nanobiotix Prognoos

Hinnasiht

By TipRanks

29.36% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR  29.36%

Kõrge 23 EUR

Madal 23 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Keskpikk perspektiiv

Weak Bearish Evidence

Bearish events outweigh bullish events.

Pikk perspektiiv

Weak Bearish Evidence

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
help-icon Live chat